A Phase 3 interventional study of Secukinumab and Placebo in Thyroid Eye Disease and Graves Orbitopathy, sponsored by Novartis Pharmaceuticals. Terminated at 5 sites in Germany. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-04-15.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Graves Ophthalmopathy with a site in Germany — none open to participants now, 5 under way, 4 of them phase 3. Graves Ophthalmopathy · Germany.
Among the 20 studies in Graves Ophthalmopathy with a site in Germany, this one is the 20th largest by enrollment, is one of 2 that started in 2021, is one of 16 in phase 3, and was the 5th registered.
199 studies on the registry are indexed under Graves Ophthalmopathy; 58 are open to participants now.
Browse Graves Ophthalmopathy studies →None of the 20 studies in Graves Ophthalmopathy with a site in Germany is open now. The open studies under Graves Ophthalmopathy, anywhere →
Of the 38 Graves Ophthalmopathy studies recruiting now, 8 (21%) set no upper age limit and 16 (42%) stop at 75 or younger; 1 takes children under 18; 9 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 16 · Phase 4 1
First in 2013; this study’s year is marked. 2 started in 2021.
This study's enrollment of 28 is below the median of 63 across 146 interventional studies indexed under Graves Ophthalmopathy.
Median enrollment 109 across the 20 interventional studies. Of the 15 that completed or were terminated, 10 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 20 have an industry lead sponsor. The 6 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Novartis has 2 studies filed under Graves Ophthalmopathy — fewer than ten, so there is no comparison to draw.
1 of the studies in Graves Ophthalmopathy with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06401044AmgenA Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease | 2027-01-06 |
Add it to your calendar (.ics) → With an account.
Among the 20 studies in Graves Ophthalmopathy with a site in Germany, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Thyroid eye disease (TED) is a rare autoimmune, inflammatory disorder of the orbit and represents the most common extra-thyroidal manifestation of Graves' disease (GD). Several lines of evidence suggest an important role of interleukin-17A (IL-17A) in the pathogenesis of TED; increased levels of IL-17A have been detected in the serum and tears of patients with TED and IL-17A levels correlate with clinical activity of the disease. T-helper 17 cells (Th17 cells) (as well as other cellular sources of IL-17A, e.g., Tc17 cells) have been shown to infiltrate the orbital tissue of affected patients, producing IL-17A. IL-17A stimulates fibroblast activation, leading to retrobulbar tissue expansion and orbital fibrosis, which causes significant functional impairment. Secukinumab is a recombinant high-affinity fully human monoclonal anti-IL-17A antibody currently approved for the treatment of 3 inflammatory/ autoimmune diseases: moderate to severe plaque psoriasis (PsO), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA) (ankylosing spondylitis (AS) and non-radiographic axSpA). The purpose of this study was to demonstrate the efficacy and safety of secukinumab 300 mg subcutaneous (s.c.) in adults with active, moderate to severe TED.
This study consisted of the following 3 periods:
Screening period (Week -6 to Baseline):
Participants' eligibility was assessed during the Screening period, which occurred for a maximum of 6 weeks.
Treatment period (Baseline to Week 16):
Eligible participants were randomized in a 1:1 ratio to one of the following double-blinded treatment arms:
Participants were stratified according to current smoking status (up to 20% smokers per arm) since smoking has a well-known impact on treatment efficacy in TED.
Follow-up/open-label retreatment period (Week 16 up to Week 108):
Proptosis non-responders (see definition below) at Week 16 were offered the option of open-label secukinumab treatment (with maintenance of blind to initial randomized treatment) for a duration of 16 weeks, i.e., up to Week 32 with last dose at Week 28, as follows:
Proptosis relapsers (see definition below) during the follow-up period (from Week 16 onward to Week 68) were offered the option of retreatment with open-label secukinumab for a duration of 16 weeks (with maintenance of blind to initial randomized treatment) at the time of relapse as follows:
Definitions of proptosis responder, non-responder and relapser:
In case of worsening of the disease, participants were allowed to receive alternative treatment for TED at the discretion of the investigator and were discontinued from the study treatment.
The primary endpoint analysis was planned to be performed once all participants had reached Week 40, which included the primary efficacy endpoint (Week 16), efficacy of retreatment for initial non-responders and relapse rates during 24 weeks of follow-up.
The final analysis was planned to be performed when the last participant had reached the end of trial.
The Food and Drug Administration (FDA) and the European Medicines Agency (EMA) expressed different preferences regarding the primary and secondary objectives and endpoints and their ordering. Therefore, this study intended to have 2 different analysis strategies and corresponding primary, secondary objective and endpoint definitions; Plan A was intended for submission in Europe (EU) and other applicable countries and Plan B was intended for submission in the United States (US) and other applicable countries. As the study was early terminated, only Plan A analysis was conducted.
Key Inclusion Criteria:
Clinical diagnosis of active, moderate to severe TED (not sight-threatening) in the study eye at Baseline associated with 2 or more of the following:
Key Exclusion Criteria:
Other protocol defined Inclusion/Exclusion may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Secukinumab 300 mg subcutaneous (s.c.) injection at Baseline, Week 1, Week 2, Week 3, Week 4, Week 8, Week 12
Drug: Secukinumab
Placebo subcutaneous (s.c.) injection at Baseline, Week 1, Week 2, Week 3, Week 4, Week 8, Week 12
Drug: Placebo
Secukinumab 300 mg s.c. at Baseline, Week 1, Week 2, Week 3, Week 4, Week 8, Week 12
Also known as: AIN457
Placebo s.c. at Baseline, Weeks 1, Week 2, Week 3, Week 4, Week 8, Week 12
Plan A - Percentage of Participants Achieving Overall Response
The percentage of participants achieving overall response was defined as follows: \>= 2 points reduction in clinical activity score (CAS) AND \>= 2 mm reduction in proptosis from Baseline in the study eye, provided there was no corresponding deterioration in CAS or proptosis (\>= 2 point or 2 mm increase, respectively) in the fellow eye after 16 weeks of treatment. Due to premature study discontinuation, purely descriptive analyses were performed for the primary endpoint.
Time frame: Baseline, Week 16
Plan B - Percentage of Participants Achieving Response in Reduction of Proptosis
The percentage of participants achieving response in reduction of proptosis at Week 16 was defined as follows: reduction of \>= 2 mm from Baseline in the study eye without deterioration (\>= 2 mm increase) of proptosis in the fellow eye. Due to premature study discontinuation, only Plan A was conducted (Plan B was not initiated) for the primary endpoint.
Time frame: Baseline, Week 16
Plan A - Percentage of Participants Achieving Response in Reduction of Clinical Activity Score (CAS)
The percentage of participants achieving response in reduction of clinical activity score (CAS) at Week 16 was defined as follows: reduction of \>= 2 points from Baseline in the study eye without deterioration (\>= 2 points increase) of CAS in the fellow eye. Due to premature study discontinuation, purely descriptive analyses were performed for the secondary endpoint.
Time frame: Baseline, Week 16
Plan A - Percentage of Participants Achieving Response in Reduction of Proptosis
The percentage of participants achieving response in reduction of proptosis at Week 16 was defined as follows: reduction of \>= 2 mm from Baseline in the study eye without deterioration (\>= 2 mm increase) of proptosis in the fellow eye. Due to premature study discontinuation, purely descriptive analyses were performed for the secondary endpoint.
Time frame: Baseline, Week 16
Plan A - Percentage of Participants Achieving Response in Diplopia
The percentage of participants achieving response in diplopia at Week 16 was defined as follows: Baseline diplopia \> 0 and a reduction of \>= 1 grade with no corresponding deterioration (\>= 1 grade worsening) in the fellow eye at Week 16. Due to premature study discontinuation, purely descriptive analyses were performed for the secondary endpoint.
Time frame: Baseline, Week 16
Plan A - Mean Change From Baseline to Week 16 in Clinical Activity Score (CAS) in the Study Eye
Thyroid Eye Disease (TED) activity was assessed using the CAS at the frequency indicated in the study schedule based on the following signs and symptoms in accordance with the European Group on Graves' Orbitopathy (EUGOGO) guideline: * Symptoms * Spontaneous retrobulbar pain * Pain on attempted upward or downward gaze * Signs * Redness of eyelids * Redness of conjunctiva * Swelling of caruncle or plica * Swelling of eyelids * Swelling of conjunctiva (chemosis) For each item present, 1 point is given. The sum of these points is the CAS score, i.e., minimum score of 0 and maximum score of 7. * Inactive TED: CAS \< 3. * Active TED: CAS \>= 3.
Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16
Plan A - Mean Change From Baseline to Week 16 in Millimeters (mm) of Proptosis in the Study Eye
Proptosis measurements were performed at the frequency indicated in the study schedule. The same Hertel instrument, and the same outer intercanthal distance, were to be used for each measurement. The mean of measurements (change from baseline in millimeters (mm) of proptosis, calculated as: (Post-Baseline value - Baseline value) / Baseline value \* 100)) for each group were presented. Due to premature study discontinuation, purely descriptive analyses were performed for the secondary endpoint.
Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16
Plan A - Percentage of Participants With Improvement in EUGOGO Disease Severity
Thyroid Eye Disease (TED) activity was assessed using the CAS at the frequency indicated in the study schedule based on the following signs and symptoms in accordance with the European Group on Graves' Orbitopathy (EUGOGO) guideline. Improvement in EUGOGO disease severity was categorized: Mild, Moderate to severe and Sight threatening.
Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16
Plan A - Graves' Ophthalmopathy Quality of Life Questionnaire (GO-QOL) Score (Score 1: Visual Functioning) Over Time
The Graves' ophthalmopathy quality of life questionnaire (GO-QOL) contains 8 questions on visual functioning and 8 questions on appearance; answers on each subscale are transformed to scores ranging from 0 (worst) to 100 (best). Due to premature study discontinuation, purely descriptive analyses were performed for the secondary endpoint.
Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16
Plan A - Graves' Ophthalmopathy Quality of Life Questionnaire (GO-QOL) Score (Score 2: Psychosocial Functioning) Over Time
The Graves' ophthalmopathy quality of life questionnaire (GO-QOL) contains 8 questions on visual functioning and 8 questions on appearance; answers on each subscale are transformed to scores ranging from 0 (worst) to 100 (best). Due to premature study discontinuation, purely descriptive analyses were performed for the secondary endpoint.
Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16
Plan A - Number of Participants With Adverse Events
The distribution of adverse events during Plan A study treatment period was done via the analysis of frequencies for Adverse Event (AEs) and Serious Adverse Event (SAEs), through the monitoring of relevant clinical and laboratory safety parameters.
Time frame: From first dose of study treatment until Week 16
Plan B - Percentage of Participants Achieving Response in Reduction of Clinical Activity Score (CAS)
The percentage of participants achieving response in reduction of CAS at Week 16 was defined as follows: reduction of \>= 2 points from Baseline in the study eye without deterioration (\>= 2 points increase) of CAS in the fellow eye. Due to premature study discontinuation, only Plan A was conducted (Plan B was not initiated) for the secondary endpoint.
Time frame: Baseline, Week 16
Plan B - Percentage of Participants Achieving Overall Response
The percentage of participants achieving overall response was defined as follows: \>= 2 points reduction in CAS AND \>= 2 mm reduction in proptosis from Baseline in the study eye, provided there was no corresponding deterioration in CAS or proptosis (\>= 2 point or 2 mm increase, respectively) in the fellow eye after 16 weeks of treatment. Due to premature study discontinuation, only Plan A was conducted (Plan B was not initiated) for the secondary endpoint.
Time frame: Baseline, Week 16
Plan B - Percentage of Participants Achieving Response in Diplopia
The percentage of participants achieving response in diplopia at Week 16 was defined as follows: Baseline diplopia \> 0 and a reduction of \>= 1 grade with no corresponding deterioration (\>= 1 grade worsening) in the fellow eye at Week 16. Due to premature study discontinuation, only Plan A was conducted (Plan B was not initiated) for the secondary endpoint.
Time frame: Baseline, Week 16
Plan B - Mean Change From Baseline to Week 16 in Clinical Activity Score (CAS) in the Study Eye.
Due to premature study discontinuation, only Plan A was conducted (Plan B was not initiated) for the secondary endpoint.
Time frame: Baseline, Week 16
Plan B - Mean Change From Baseline to Week 16 in Proptosis in the Study Eye.
Proptosis is the protrusion of the eyeball. Exophthalmos means the same, and this term is usually used when describing proptosis due to Grave's disease. Due to premature study discontinuation, only Plan A was conducted (Plan B was not initiated) for the secondary endpoint.
Time frame: Baseline, Week 16
Plan B - Mean Change From Baseline to Week 16 in the Graves' Ophthalmopathy Quality of Life Questionnaire (GO-QOL) Score (Score 1: Visual Functioning)
The Graves' ophthalmopathy quality of life questionnaire (GO-QOL) contains 8 questions on visual functioning and 8 questions on appearance; answers on each subscale are transformed to scores ranging from 0 (worst) to 100 (best). Due to premature study discontinuation, only Plan A was conducted (Plan B was not initiated) for the secondary endpoint.
Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16
Plan B - Mean Change From Baseline to Week 16 in the Graves' Ophthalmopathy Quality of Life Questionnaire (GO-QOL) Score (Score 2: Psychosocial Functioning)
The Graves' ophthalmopathy quality of life questionnaire (GO-QOL) contains 8 questions on visual functioning and 8 questions on appearance; answers on each subscale are transformed to scores ranging from 0 (worst) to 100 (best). Due to premature study discontinuation, only Plan A was conducted (Plan B was not initiated) for the secondary endpoint.
Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16
Plan B - Number of Participants With Adverse Events
Due to premature study discontinuation, only Plan A was conducted (Plan B was not initiated) for the secondary endpoint.
Time frame: From first dose of study treatment until Week 16
This study was conducted at 5 centers in Germany.
| Milestone | Secukinumab 300 mg | Placebo |
|---|---|---|
| Started | 14 | 14 |
| Completed | 12 | 12 |
| Not completed | 2 | 2 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Study terminated by sponsor | 1 | 2 |
| Milestone | Secukinumab 300 mg | Placebo |
|---|---|---|
| Started | 12 | 12 |
| Completed | 8 | 9 |
| Not completed | 4 | 3 |
| Withdrew: Not satisfied | 1 | 0 |
| Withdrew: Study terminated by sponsor | 3 | 1 |
| Withdrew: No benefit imp | 0 | 1 |
| Withdrew: Therapy national guidelines | 0 | 1 |
The percentage of participants achieving overall response was defined as follows: \>= 2 points reduction in clinical activity score (CAS) AND \>= 2 mm reduction in proptosis from Baseline in the study eye, provided there was no corresponding deterioration in CAS or proptosis (\>= 2 point or 2 mm increase, respectively) in the fellow eye after 16 weeks of treatment. Due to premature study discontinuation, purely descriptive analyses were performed for the primary endpoint.
| Participants | Secukinumab 300 mg | Placebo |
|---|---|---|
| Yes | 0 | 0 |
| No | 12 | 11 |
| Missing | 2 | 3 |
The percentage of participants achieving response in reduction of proptosis at Week 16 was defined as follows: reduction of \>= 2 mm from Baseline in the study eye without deterioration (\>= 2 mm increase) of proptosis in the fellow eye. Due to premature study discontinuation, only Plan A was conducted (Plan B was not initiated) for the primary endpoint.
No measurements were reported for this outcome.
The percentage of participants achieving response in reduction of clinical activity score (CAS) at Week 16 was defined as follows: reduction of \>= 2 points from Baseline in the study eye without deterioration (\>= 2 points increase) of CAS in the fellow eye. Due to premature study discontinuation, purely descriptive analyses were performed for the secondary endpoint.
| Participants | Secukinumab 300 mg | Placebo |
|---|---|---|
| Yes | 0 | 3 |
| No | 12 | 8 |
| Missing | 2 | 3 |
The percentage of participants achieving response in reduction of proptosis at Week 16 was defined as follows: reduction of \>= 2 mm from Baseline in the study eye without deterioration (\>= 2 mm increase) of proptosis in the fellow eye. Due to premature study discontinuation, purely descriptive analyses were performed for the secondary endpoint.
| Participants | Secukinumab 300 mg | Placebo |
|---|---|---|
| Yes | 0 | 0 |
| No | 12 | 11 |
| Missing | 2 | 3 |
The percentage of participants achieving response in diplopia at Week 16 was defined as follows: Baseline diplopia \> 0 and a reduction of \>= 1 grade with no corresponding deterioration (\>= 1 grade worsening) in the fellow eye at Week 16. Due to premature study discontinuation, purely descriptive analyses were performed for the secondary endpoint.
| Participants | Secukinumab 300 mg | Placebo |
|---|---|---|
| Yes | 1 | 1 |
| No | 11 | 11 |
| Missing | 2 | 2 |
Thyroid Eye Disease (TED) activity was assessed using the CAS at the frequency indicated in the study schedule based on the following signs and symptoms in accordance with the European Group on Graves' Orbitopathy (EUGOGO) guideline: * Symptoms * Spontaneous retrobulbar pain * Pain on attempted upward or downward gaze * Signs * Redness of eyelids * Redness of conjunctiva * Swelling of caruncle or plica * Swelling of eyelids * Swelling of conjunctiva (chemosis) For each item present, 1 point is given. The sum of these points is the CAS score, i.e., minimum score of 0 and maximum score of 7. * Inactive TED: CAS \< 3. * Active TED: CAS \>= 3.
| Unit on a scale | Secukinumab 300 mg | Placebo |
|---|---|---|
| Change from BL at Week 2 | -0.21 ± 0.58 | -0.29 ± 0.47 |
| Change from BL at Week 4 | -0.14 ± 1.10 | -0.29 ± 0.73 |
| Change from BL at Week 8 | 0.00 ± 1.00 | -0.21 ± 0.58 |
| Change from BL at Week 12 | -0.67 ± 1.15 | -0.57 ± 0.94 |
| Change from BL at Week 16 | 0.00 ± 0.95 | -0.73 ± 1.10 |
Proptosis measurements were performed at the frequency indicated in the study schedule. The same Hertel instrument, and the same outer intercanthal distance, were to be used for each measurement. The mean of measurements (change from baseline in millimeters (mm) of proptosis, calculated as: (Post-Baseline value - Baseline value) / Baseline value \* 100)) for each group were presented. Due to premature study discontinuation, purely descriptive analyses were performed for the secondary endpoint.
| millimeters (mm) | Secukinumab 300 mg | Placebo |
|---|---|---|
| Change from BL at Week 2 | 0.18 ± 0.72 | -0.07 ± 0.73 |
| Change from BL at Week 4 | 0.18 ± 0.72 | 0.00 ± 1.18 |
| Change from BL at Week 8 | 0.42 ± 1.00 | 0.43 ± 1.28 |
| Change from BL at Week 12 | 0.67 ± 0.98 | 0.29 ± 1.33 |
| Change from BL at Week 16 | 0.83 ± 1.03 | 0.64 ± 1.03 |
Thyroid Eye Disease (TED) activity was assessed using the CAS at the frequency indicated in the study schedule based on the following signs and symptoms in accordance with the European Group on Graves' Orbitopathy (EUGOGO) guideline. Improvement in EUGOGO disease severity was categorized: Mild, Moderate to severe and Sight threatening.
| Participants | Secukinumab 300 mg | Placebo |
|---|---|---|
| Baseline — Mild | 0 | 0 |
| Baseline — Moderate to severe | 14 | 14 |
| Baseline — Sight threatening | 0 | 0 |
| Week 2 — Mild | 0 | 0 |
| Week 2 — Moderate to severe | 14 | 14 |
| Week 2 — Sight threatening | 0 | 0 |
| Week 4 — Mild | 1 | 1 |
| Week 4 — Moderate to severe | 13 | 12 |
| Week 4 — Sight threatening | 0 | 0 |
| Week 8 — Mild | 0 | 1 |
| Week 8 — Moderate to severe | 13 | 13 |
| Week 8 — Sight threatening | 0 | 0 |
| Week 12 — Mild | 1 | 1 |
| Week 12 — Moderate to severe | 11 | 13 |
| Week 12 — Sight threatening | 0 | 0 |
| Week 16 — Mild | 1 | 1 |
| Week 16 — Moderate to severe | 11 | 10 |
| Week 16 — Sight threatening | 0 | 0 |
The Graves' ophthalmopathy quality of life questionnaire (GO-QOL) contains 8 questions on visual functioning and 8 questions on appearance; answers on each subscale are transformed to scores ranging from 0 (worst) to 100 (best). Due to premature study discontinuation, purely descriptive analyses were performed for the secondary endpoint.
| Unit on a scale | Secukinumab 300 mg | Placebo |
|---|---|---|
| Baseline | 64.1 ± 23.04 | 66.6 ± 24.38 |
| Week 2 | 62.9 ± 27.71 | 66.4 ± 20.51 |
| Week 4 | 56.7 ± 28.11 | 66.7 ± 23.82 |
| Week 8 | 51.0 ± 27.93 | 59.1 ± 24.75 |
| Week 12 | 54.7 ± 29.45 | 60.8 ± 28.71 |
| Week 16 | 52.1 ± 29.36 | 61.9 ± 30.42 |
The Graves' ophthalmopathy quality of life questionnaire (GO-QOL) contains 8 questions on visual functioning and 8 questions on appearance; answers on each subscale are transformed to scores ranging from 0 (worst) to 100 (best). Due to premature study discontinuation, purely descriptive analyses were performed for the secondary endpoint.
| Unit on a scale | Secukinumab 300 mg | Placebo |
|---|---|---|
| Baseline | 65.6 ± 22.43 | 60.3 ± 20.60 |
| Week 2 | 68.3 ± 16.16 | 62.5 ± 29.42 |
| Week 4 | 69.2 ± 21.01 | 56.7 ± 30.37 |
| Week 8 | 65.4 ± 20.51 | 52.2 ± 30.87 |
| Week 12 | 63.5 ± 26.09 | 53.1 ± 34.47 |
| Week 16 | 66.2 ± 26.84 | 56.8 ± 30.55 |
The distribution of adverse events during Plan A study treatment period was done via the analysis of frequencies for Adverse Event (AEs) and Serious Adverse Event (SAEs), through the monitoring of relevant clinical and laboratory safety parameters.
| Participants | Secukinumab 300 mg | Placebo |
|---|---|---|
| Any adverse event (AE) | 9 | 6 |
| Study treatment related AE | 3 | 1 |
| AE leading to study treatment discontinuation | 0 | 0 |
| Serious adverse event (SAE) | 0 | 1 |
| Study treatment related SAE | 0 | 0 |
| SAE leading to study treatment discontinuation | 0 | 0 |
The percentage of participants achieving response in reduction of CAS at Week 16 was defined as follows: reduction of \>= 2 points from Baseline in the study eye without deterioration (\>= 2 points increase) of CAS in the fellow eye. Due to premature study discontinuation, only Plan A was conducted (Plan B was not initiated) for the secondary endpoint.
No measurements were reported for this outcome.
The percentage of participants achieving overall response was defined as follows: \>= 2 points reduction in CAS AND \>= 2 mm reduction in proptosis from Baseline in the study eye, provided there was no corresponding deterioration in CAS or proptosis (\>= 2 point or 2 mm increase, respectively) in the fellow eye after 16 weeks of treatment. Due to premature study discontinuation, only Plan A was conducted (Plan B was not initiated) for the secondary endpoint.
No measurements were reported for this outcome.
The percentage of participants achieving response in diplopia at Week 16 was defined as follows: Baseline diplopia \> 0 and a reduction of \>= 1 grade with no corresponding deterioration (\>= 1 grade worsening) in the fellow eye at Week 16. Due to premature study discontinuation, only Plan A was conducted (Plan B was not initiated) for the secondary endpoint.
No measurements were reported for this outcome.
Due to premature study discontinuation, only Plan A was conducted (Plan B was not initiated) for the secondary endpoint.
No measurements were reported for this outcome.
Proptosis is the protrusion of the eyeball. Exophthalmos means the same, and this term is usually used when describing proptosis due to Grave's disease. Due to premature study discontinuation, only Plan A was conducted (Plan B was not initiated) for the secondary endpoint.
No measurements were reported for this outcome.
The Graves' ophthalmopathy quality of life questionnaire (GO-QOL) contains 8 questions on visual functioning and 8 questions on appearance; answers on each subscale are transformed to scores ranging from 0 (worst) to 100 (best). Due to premature study discontinuation, only Plan A was conducted (Plan B was not initiated) for the secondary endpoint.
No measurements were reported for this outcome.
The Graves' ophthalmopathy quality of life questionnaire (GO-QOL) contains 8 questions on visual functioning and 8 questions on appearance; answers on each subscale are transformed to scores ranging from 0 (worst) to 100 (best). Due to premature study discontinuation, only Plan A was conducted (Plan B was not initiated) for the secondary endpoint.
No measurements were reported for this outcome.
Due to premature study discontinuation, only Plan A was conducted (Plan B was not initiated) for the secondary endpoint.
No measurements were reported for this outcome.
Collected over Adverse events are presented for the double-blind treatment period (from first dose of study treatment until Week 16) and for the follow-up/open-label re-treatment period, including AEs in follow up for all patients who received at least one dose of Secukinumab during the entire study up to a maximum of 108 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Secukinumab 300 mg (Double-blind) | 0/14 (0%) | 1/14 (7.1%) | 12/14 (85.7%) |
| Placebo (Double-blind) | 0/14 (0%) | 1/14 (7.1%) | 12/14 (85.7%) |
| Any Secukinumab 300 mg (Entire Study) | 0/26 (0%) | 1/26 (3.8%) | 23/26 (88.5%) |
| Event | Secukinumab 300 mg (Double-blind) | Placebo (Double-blind) | Any Secukinumab 300 mg (Entire Study) |
|---|---|---|---|
| Graves' diseaseEndocrine disorders | 1/14 | 0/14 | 1/26 |
| Endocrine ophthalmopathyEye disorders | 0/14 | 1/14 | 0/26 |
| Event | Secukinumab 300 mg (Double-blind) | Placebo (Double-blind) | Any Secukinumab 300 mg (Entire Study) |
|---|---|---|---|
| COVID-19Infections and infestations | 4/14 | 6/14 | 10/26 |
| Urinary tract infectionInfections and infestations | 0/14 | 3/14 | 2/26 |
| HeadacheNervous system disorders | 3/14 | 2/14 | 5/26 |
| FatigueGeneral disorders | 2/14 | 0/14 | 2/26 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/14 | 0/14 | 2/26 |
| HypertensionVascular disorders | 1/14 | 2/14 | 3/26 |
| LymphadenopathyBlood and lymphatic system disorders | 1/14 | 0/14 | 1/26 |
| NeutropeniaBlood and lymphatic system disorders | 1/14 | 0/14 | 1/26 |
| VertigoEar and labyrinth disorders | 1/14 | 0/14 | 1/26 |
| Thyroid dermatopathyEndocrine disorders | 0/14 | 1/14 | 1/26 |
| Age, Continuous(Years) | Secukinumab 300 mg | Placebo | Total |
|---|---|---|---|
| Mean | 53.6 ± 11.85 | 57.7 ± 10.64 | 55.6 ± 11.25 |
| Sex: Female, Male(Participants) | Secukinumab 300 mg | Placebo | Total |
|---|---|---|---|
| Female | 9 | 12 | 21 |
| Male | 5 | 2 | 7 |
| Race/Ethnicity, Customized(Participants) | Secukinumab 300 mg | Placebo | Total |
|---|---|---|---|
| White | 14 | 14 | 28 |
| Smoking History(Participants) | Secukinumab 300 mg | Placebo | Total |
|---|---|---|---|
| Current | 3 | 4 | 7 |
| Former | 8 | 6 | 14 |
| Never | 3 | 4 | 7 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Nov 2021 to primary completion in May 2023, 17 months.
Results were first posted in Jan 2025, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Secukinumab